Sugarbaker, P. H., & Van der Speeten, K. (2021). The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol.
استشهاد بنمط شيكاغوSugarbaker, Paul H., و Kurt Van der Speeten. "The PRODIGE 7 Randomized Trial Has 4 Design Flaws and 4 Pharmacologic Flaws and Cannot Be Used to Discredit Other HIPEC Regimens." J Gastrointest Oncol 2021.
MLA استشهادSugarbaker, Paul H., و Kurt Van der Speeten. "The PRODIGE 7 Randomized Trial Has 4 Design Flaws and 4 Pharmacologic Flaws and Cannot Be Used to Discredit Other HIPEC Regimens." J Gastrointest Oncol 2021.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.